RL-007 is a small molecule commercialized by Atai Life Sciences, with a leading Phase II program in Cognitive Impairment Associated With Schizophrenia (CIAS).
The importance of the brain renin-angiotensin system in cardiovascular function is well accepted. However, not knowing the precise source of renin in the brain has been a limitation toward a complete ...